Please try another search
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company’s lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Name | Age | Since | Title |
---|---|---|---|
David A. Happel | 61 | 2022 | CEO, President & Director |
Beth C. Seidenberg | 66 | 2007 | Independent Director |
George W. Kemble | 62 | 2011 | Executive Chairman of the Board |
Merdad V. Parsey | 60 | 2010 | Independent Director |
Paul W. Hoelscher | 59 | 2024 | Independent Director |
Elizabeth A. Grammer | 60 | 2021 | Independent Director |
Timothy P. Walbert | 57 | 2024 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review